Noventure grants Pharmaforce exclusive distribution right for its product Tasectan® AF in the countries Denmark, Sweden, Finland and Norway.

Noventure grants Pharmaforce exclusive distribution right for its product Tasectan® AF in the countries Denmark, Sweden, Finland, and Norway. Tasectan® AF is intended to restore the physiological functions of the intestinal walls. It is specifically formulated for the control and reduction of the symptoms related to diarrheal events of different [...]

Read More
Noventure | Xyloglucan, a Plant Polymer with Barrier Protective Properties over the Mucous Membranes: An Overview

Xyloglucan, a Plant Polymer with Barrier Protective Properties over the Mucous Membranes: An Overview

Int. J. Mol. Sci. 2018, 19(3), 673 Abstract Disruption of the epithelial barrier function has been recently associated with a variety of diseases, mainly at intestinal level, but also affecting the respiratory epithelium and other mucosal barriers. Non-pharmacological approaches such as xyloglucan, with demonstrated protective barrier properties, are proposed as [...]

Read More

Efficacy of gelatin tannate for acute diarrhea in children: a systematic review and meta-analysis.

Aloi M, Mennini M. J Comp Eff Res. 2018 Nov 22. Efficacy of gelatin tannate for acute diarrhea in children: a systematic review and meta-analysis. AIM: To investigate by meta-analysis the efficacy of gelatin tannate (GT), a mucosal barrier protector, in children with acute gastroenteritis. METHODS: A comprehensive literature search [...]

Read More
Noventure presents its pediatric range at the 51st ESPGHAN Annual Meeting in Geneva, 09-12 May 2018

Noventure presents its pediatric range at the 51st ESPGHAN Annual Meeting in Geneva, 09-12 May 2018

As in previous years, Noventure has participated in the ESPGHAN Congress, held in Geneva, 09-12 May 2018. Pediatric gastroenterologists are a key target group for the recommendation and endorsement of new approaches to GI conditions in children. 4.627 delegates from 100 countries participated at the congress, and many of them [...]

Read More
Noventure is delighted to announce the launch of Tasectan® in Russia by its partner company Jadran, under…

Noventure is delighted to announce the launch of Tasectan® in Russia by its partner company Jadran, under the umbrella brand Adiarin®

Adiarin®  is recommended for the protection of gut lining in diarrhea in children and adults. It is the first Noventure product in Russia. Tasectan® in Europe is a class III medical device and complies with the Essential Requirements of Directive 93/42/EEC and subsequent amendments. (CE 0373, Novinthetical Pharma SA). In [...]

Read More
Noventure | New scientific publication on Mucoprotection and diarrheal processes.

New scientific publication on Mucoprotection and diarrheal processes.

Szajewska H, Kołodziej M, Łukasik J. Drug development and acute gastrointestinal infections. Expert Opin Investig Drugs. 2017 Dec 26:1-6  Expert Opin Investig Drugs. 2017 Dec 26:1-6.   NO ABSTRACT AVAILABLE Mucoprotectans chapter: 4. Mucosal protective agents Clarifying the role of intestinal mucus in reducing inflammation and infection has led to the [...]

Read More